PRAME

So we've obviously looked across what other companies, the competitive intelligence in this space, what others are doing, and we have picked targets that others aren't working on.

and really have been learning from what these other companies have been doing, so looking at the epitope copy numbers of PRAME on the cell surface, what cancers are presenting PRAME, and then looking at how we can differentiate ourselves on that.

So the targets that we've come up with, they're the two lead programmes, so TC25 and TC11.

TC25 is a target that's highly expressed on head and neck cancers, oesophageal cancers and lung cancers.

So a target that's more abundant in tumours that are also expressing PRAME but we can attack more cancer cells using the target that we're going after.

So very differentiated from other targets like PRAME.

And then our other programme, which is TC11, is in the melanoma space, which again has lots of activity in terms of other drugs, but really what's making us differentiated with the molecule that we've developed.

Again, the abundance of that target, and so some of the translational data that we've now generated is demonstrating that we can kill these checkpoint resistant tumours with the target and the bispecific that we've generated.